50results about How to "Expansion of medical use" patented technology

The present invention relates to the new use of narigenin and similar compounds in preparing medicines for treating cardiac and cerebral vascular diseases. These compounds include narigenin and its derivative, hesperidene and its derivative, isosakuranetin and its derivative, eriodictyol and its derivative, etc. These compounds may be used in preventing, diagnosing and treating cerebral infarction, myocardial infarction, cerebral ischemia-reperfusion injury, myocardial ischemia-reperfusion injury and other cardiac and cerebral vascular diseases as well as Alzheimer disease and its relevant diseases. These compounds have high pharmacological action, low toxicity, wide material source, low cost and other advantages.

The invention relates to the use of vanillic aldehyde receptor activator in preparing products against Alzheimer's disease, wherein the vanillic aldehyde receptor activator comprises vanillic aldehyde and its derivative, capsaicin analogue and derivatives.

The invention relates to application of polydatin which is an extract of polygonum cuspidatum. In-vitro researching experiments show that the polydatin has strong protecting effect for pathological injuries caused by rats multiple infarctional cerebral ischemic injuries, can significantly improve learning memory function of dementia model rats, so the polydatin can be used for preparing a product for resisting vascular dementia and a product, particularly a medicine for resisting senile dementia. The modes for using the polydatin include independent use, or combined use with other chemical substances. Dementia is a key disease impacting health of the elderly, particularly, frequency of disease development of the vascular dementia and the senile dementia is significantly increased to seriously threaten health and life of human beings. The invention provides a novel drug source for clinically treating the vascular dementia and the senile dementia, and has important value for developing and utilizing medicinal plant resource in China.

The present invention relates to the new use of total timosaponin as one Chinese medicine extract. The extract has timosaponin B-II compound as main component in the content of 30-70 % and is obtained through conventional extraction, separation and purification process. The extract has powerful pharmaceutical effect of diagnosing and treating myocardial ischemia and relevant diseases. It has simple preparation process, high yield, stable chemical property and safety and use wide application range.

The invention relates to Brefeldin A-producing bacteria, a preparation method, a method for preparing the brefeldin A by fermentation and the application thereof. The Brefeldin A-producing bacteria has the advantages of easy selection, cultivation and storage, low cost, simple process, short preparation period, high yield, no usage of toxic raw material, less organic solvent, thorough guarantee of medicine resource, potential of mass production and favorable economic and social benefits, contributes to the maintenance of ecological balance and the protection of natural resources. The fermentation product of the invention, of which the main component is THSG, develops novel medical application, the Brefeldin A has high safety, low toxicity, stable property, stronger pharmacological action, simple preparation process, high yield and considerably wide range of application, is multipurpose, and can provide a novel source for medicines for preventing, diagnosing, detecting, protecting, curing and researching antimycotic, antiviral and antineoplastic diseases and the directly related diseases.

The invention relates to application of oligomeric proantho cyanidins in preparing products for preventing, diagnosing, detecting, protecting, treating and studying vascular dementia and directly related diseases thereof, in particular to new application in medicament and health-care products. Experiments prove that oligomeric proantho cyanidins can improve the study memory ability of a heart and brain ischemia-reperfusion mouse and a permanent bilateral common carotid arteries rat, inhibit lipid peroxidation in brains of the heart and brain ischemia-reperfusion mouse and the permanent bilateral common carotid arteries rat, and improve the superoxide dismutase enzyme activity of the heart and brain ischemia-reperfusion mouse and the permanent bilateral common carotid arteries rat. The oligomeric proantho cyanidins have strong action, clear effect, rich resource, simple preparation process, high yield, stable property and safe use, in particular one object with multiple functions and wide application range, and can play roles furthest. Disease rate of dementia rises gradually, after popularization, the application of oligomeric proantho cyanidins can generate significant social benefit and economic benefit in short time.

The present invention relates to purposes of giant knotweed extract. The in vitro anti-HIV experiment shows that resveratrol 3-O-Beta-D- glucoside 2íÕ-sulfate sodium or potash salt and resveratrol 3-O-Beta-D- glucoside 4íÕ-sulfate sodium or potash salt show significant activity of resisting hepatitis B virus; resveratrol 3-O-Beta-D- glucoside 2íÕ-sulfate sodium or potash salt also has significant HIV inhibited effect. The virus infectious diseases such as AIDS and hepatitis B poses a serious threat to human's health and life and hepatitis B is one of the major diseases affecting human's health. The present invention provides a lead compound for doing R&D of novel anti-HIV and hepatitis B virus medicines and also a novel medicine source for clinic application, thus having a significant value to develop and utilize the medical plant resources of our country.

The invention relates to a medicine treating carcinoma of colon and the method for preparing the same, which in detail is aglycone extract from root of Patrinia scabra Bge and the preparation method. The effective component is iridoid glycosides aglycone, the content is above 40%. The invention also provides the medicine agent and preparation. It is proved by pharmacologia test that the medicine is characterized by safe utilization, function of preventing the weight of tumor in transplanted carcinoma of colon. The extract can be produced into preparations of tablet, capsule, drop pill, granular or oral.

The invention relates to the technical field of biological medicines and in particular relates to a novel use of pentapeptide and metabolite thereof in preparation of an anti-dementia product. Amino acid sequences of the small peptide are as shown in Seq No.1, No.2, No.3, No.4, No.5 and No.6. According to the pharmacological experiment of the alzheimer disease and vascular dementia animal model, the small peptide and the metabolite thereof can be used for remarkably improving the cognitive function of the dementia, so that the small peptide and the metabolite thereof have the effects of preventing the alzheimer disease and vascular dementia, and therefore, the pentapeptide and metabolite thereof can be used for preparing the medicine for preventing senile dementia including the alzheimer disease and vascular dementia.

The invention relates to a melamine antigen, a related antibody and a preparation method thereof. Melamine and carrier protein are coupled by using PAD (polyaldehyde dextran) as bridge reagent; coupling products is used to immunize animals to prepare monoclonal antibodies for detecting melamine. Artificially-prepared melamine antigen and related antibody provided by the invention can be used for researching and developing melamine immunity detection reagents to meet detection demand on low cost, rapidity and convenient operations.

The invention discloses application of anthocyanin in preparation of drugs for treating cell injury caused by arsanilic acid. An in-vitro chick embryo fibroblast DF-1 cell model is established for studying application of arsanilic acid and anthocyanin in apoptosis of DF-1 cells. The application of arsanilic acid and the anthocyanin in apoptosis of the DF-1 cells firstly discovers that arsanilic acid has cytotoxicity on the DF-1 cells and is capable of inducing the apoptosis. The anthocyanin with a certain concentration being 50-100 micrograms per milliliter can resist the apoptosis caused by arsanilic acid; the medical application of the anthocyanin is expanded; the development of drugs taking the anthocyanin as an effective component and having new indications can be facilitated.

The invention relates to a target protein which takes a betaB2 crystal protein to improve the spermatogensis and a novel application thereof. A betaB2 crystal protein knockout mouse model is used for analyzing the expression of the betaB2 crystal protein in mouse testis tissues to confirm the reduction of CaMKIV expression and activity, caused by betaB2 crystal protein knockout, so as to reduce a reproductive function; and a CaMKIV expression level is reduced so that the expression of Bcl-2 is reduced to enable testis germ cells to be excessively proliferated and apoptotic and damage sperms. Therefore, the target protein for improving the spermatogensis is the betaB2 crystal protein, and a novel medicine resource and a novel application preparation are provided; and the target protein has the very important value for improving the existing medical level. The target protein disclosed by the invention is safe and cheap, effective in treatment and stable in property, is suitable for large-scale production and business application of industries of medicines, reagents and the like, is easy to popularize and apply, has a very good application prospect, and has obvious social benefits and economic benefits.

The invention discloses application of 4-hydroxyl-2-pyridone alkaloid in preparing an antitumor product. The 4-hydroxyl-2-pyridone alkaloid is Sambutoxin, and a chemical structure of the 4-hydroxyl-2-pyridone alkaloid is shown in the description. Through researches of animal experiments, cell experiments and the like, the compound is shown to have very strong antitumor activity on varieties of tumor cells including lung cancer, cervical cancer, colon cancer and breast cancer; the compound has the advantages of obvious effects, safety, low toxin, convenience in use and rich and cheap raw material sources; a preparation technology has the advantages of simpleness, high yield, stable characters, convenience in quality control, lower production cost and convenience in application production; anovel medicine source and a safe raw material are provided for treating and researching antitumor and direct related diseases of the antitumor.

The invention relates to the technical field of medicines, healthcare products and the like, and particularly to a new application of procyanidine B2 related to active Chinese medicine components in preparation of products, especially medicines and healthcare products for preventing, diagnosing, detecting, protecting, treating and researching vascular dementia, alzheimer disease and diseases directly related to vascular dementia and alzheimer disease. Experiments prove that the procyanidine B2 can enhance the learning and memory capabilities of a mouse with vascular dementia caused by global cerebral ischemia reperfusion injury, a rat with vascular dementia caused by cerebral ischemia reperfusion injury, and a rat with alzheimer disease caused by beta amyloid protein. The compound is strong in action, obvious in effect, abundant in source, stable in property, safe in use, especially wide in use range, and capable of furthest exerting the action thereof. The incidence rate of dementia continuously rises, and the new applciation of procyanidine B2 can generate remarkable social benefits and economic benefits in a short time after being popularized.

The invention relates to the technical field of biomedicine, and in particular relates to a new application of partial metabolite of pentapeptide in preparation of a myocardial ischemia resistant product. The amino acid sequence of the small peptide is shown as Seq No.2, No.3, No.4, No.5, No.6 and No.7. Through pharmacological experiments of acute rat myocardial ischemia and damage models, the small peptide and the metabolite thereof can remarkably reduce the range of rat myocardial damage and myocardial infarction caused by myocardial ischemia, reduce the content of lactic dehydrogenase and creatine kinase in myocardial ischemia rat serum and have the function of preventing and treating the myocardial ischemia, so the small peptide and the metabolite thereof can be used for preparing a medicament for preventing and treating the myocardial ischemia.

An anti-tumor Chinese medicine product comprises medicine, reagent, food and drink and is characterized in that the effective component of the Chinese medicine product is a betulic acid liposome containing betulic acid. The entrapment rate of the betulic acid liposome reaches over 90 percent and particle diameter is 100 to 1000 nanometers. Firstly, the betulic acid plastid is obtained by membrane process; and then the single betulic acid liposome or the betulic acid liposome as well as other chemical substances comprising a pharmaceutically acceptable carrier, the food, a natural product, synthetic chemicals or medicine composition for human are made into the medicine, the food or the drink by general process.

The invention discloses an application of platycodon grandiflorum(Jacq)A .DC polysaccharide for preparing a medicine capable of treating cellular damage caused by Cr(VI). A model for chicken embryo fibroblast line (DF-1 cell) cellular damage caused by Cr(VI) is established to research the function of the platycodon grandiflorum(Jacq)A .DC polysaccharide in the cellular damage. The invention discovers for the first time that the platycodon grandiflorum(Jacq)A .DC polysaccharide of a certain concentration (50-200[mu]g/ml) can resist the cellular damage caused by Cr(VI). The medical application of the platycodon grandiflorum(Jacq)A .DC polysaccharide is widened, and the invention is favorable for developing medicines which take the platycodon grandiflorum(Jacq)A .DC polysaccharide as an effective ingredient and have new indications.

The invention discloses application of Edo sakuranin to treatment of Alzheimer. The application has the advantages that experiments prove that the Edo sakuranin can promote the proliferation rate andactivity of a PC-12 cell damaged by A Beta 25-35 and meanwhile can inhibit apoptosis of the PC-12 cell damaged by A Beta 25-35, and a novel method for the treatment of Alzheimer is provided.